Page 3 - Nuclear Export News Today

NEWTON, Mass., Dec. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has been assigned an average rating of “Moderate Buy” from the six ratings firms that are covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price […]

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the six research firms that are covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year price target among […]

Karyopharm Therapeutics (NASDAQ:KPTI – Free Report) had its price target cut by Royal Bank of Canada from $4.00 to $3.00 in a report published on Friday morning, Benzinga reports. They currently have an outperform rating on the stock. Several other equities analysts have also commented on the company. Wedbush reiterated a neutral rating and issued […]

Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) had its price target dropped by Piper Sandler from $7.00 to $5.00 in a report released on Friday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Piper Sandler’s target price would suggest a potential upside of 461.80% from the company’s current price. Other equities […]

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Selinexor is under clinical development by Karyopharm Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer.

-- Conference Call Scheduled for Thursday, November 2, 2023, at 8:00 a.m. ET -- NEWTON, Mass., Oct. 26, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) saw a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 16,640,000 shares, a growth of 10.6% from the September 15th total of 15,040,000 shares. Based on an average trading volume of 2,150,000 shares, the days-to-cover ratio […]